Condition: Bile Duct Cancer · Sponsor: Insel Gruppe AG, University Hospital Bern
The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of systemic anti-tumor therapy with or without immune-checkpoint-inhibitor (ICI). The main question it aims to answer is whether it is safe to combine systemic anti-tumor therapy with or without ICI with and bRFA. Participants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and systemic anti-tumor therapy, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined. Researchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate.
This description comes directly from the study's public registry record.
Prof. Dr. med. Reiner Wiest · +41 31 632 59 41 · reiner.wiest@insel.ch
Prof. Dr. med. Martin Berger · +41 31 632 41 14 · martin.berger@insel.ch
Always discuss trial participation with your own doctor first.
| Inselspital Bern University Hospital | Bern, Switzerland | Recruiting |
| Hôpitaux Universitaires Genève | Geneva, Switzerland | Not Yet Recruiting |
| Luzerner Kantonspital | Lucerne, Switzerland | Not Yet Recruiting |
| Universitätsspital Zürich | Zurich, Switzerland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06274879